Human Papilloma Virus Infection and Prevention in the Adolescent Population

Journal of Pediatric and Adolescent Gynecology

Volumn 22, Issue 4, 2009, Pages 197-204

  Hager, W David ^a  

^a CENTRAL BAPTIST HOSPITAL   (United States)

Author keywords

HPV immunization; HPV screening; Human papillomavirus (HPV); Sexually transmitted infection (STI); Vaccine implementation

Indexed keywords

ALUMINUM SULFATE; VIRUS VACCINE; WART VIRUS VACCINE;

ADJUVANT THERAPY; ADOLESCENT; BIOPSY; CANCER INVASION; CANCER MORTALITY; CANCER SCREENING; CLINICAL EVALUATION; CLINICAL TRIAL; CONDOM; CONDYLOMA ACUMINATUM; CYTOLOGY; DISEASE COURSE; DISEASE SEVERITY; DNA HYBRIDIZATION; DRUG EFFICACY; DRUG SAFETY; GYNECOLOGICAL EXAMINATION; HEALTH SURVEY; HUMAN; HYSTERECTOMY; IMMUNIZATION; INFECTION PREVENTION; INFECTION RISK; INVASIVE CERVICAL CANCER; LABORATORY TEST; PAPANICOLAOU TEST; PERSISTENT INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; SCREENING; SEXUAL TRANSMISSION; SEXUALLY TRANSMITTED DISEASE; SHORT SURVEY; TREATMENT DURATION; UTERINE CERVIX CANCER; UTERINE CERVIX DISEASE; VACCINATION; VERRUCA VULGARIS; VIRUS LIKE AGENT; WART VIRUS;

ADOLESCENT; FEMALE; HUMANS; MASS IMMUNIZATION; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; YOUNG ADULT;

EID: 67651085420     PISSN: 10833188     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpag.2008.01.079     Document Type: Short Survey

References (25)

1. Weinstock H., Berman S., and Cates Jr. W. Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. Perspect Sex Reprod Health 35 (2004) 6
2. Centers for Disease Control and Prevention. MMWR Morbid Mortal Wkly Rep. 2007;56(RR-2):1-24.
3. Munoz N., Bosch F.X., Castellsagué X., et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 111 (2004) 278
4. Winer R.L., Lee S.K., Hughes J.P., et al. Genital human papillomavirus infection: Incidence and risk factors in a cohort of female university students. Am J Epidemiol 157 (2003) 218
5. Zur Hansen H., de Villiers E.M., and Gissmann L. Papillomavirus infections and human genital cancer. Gynecol Oncol 2 (1981) S124
6. Schiffman M., and Castle P.E. Human papillomavirus: epidemiology and public health. Arch Pathol Lab Med 127 (2003) 930
7. Parkin D.M., Bray F., Ferlay J., et al. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74
8. Bergeron C., Bishop J., Lemarie A., et al. Accuracy of thin-layer cytology in patients undergoing cervical cone biopsy. Acta Cytol 45 (2001) 519
9. American Cancer Society. Cancer Facts and Figures 2007 (2007), American Cancer Society, Atlanta
10. Fitch J.T., Stine C., Hager W.D., et al. Condom effectiveness: Factors that influence risk reduction. Sex Trans Dis 29 (2002) 811
11. Holmes K.K., Levine R., and Weaver M. Effectiveness of condoms in preventing sexually transmitted infections. Bull WHO 82 (2004) 454
12. Wong E.L., Roddy R.E., Tucker H., et al. Use of male condoms during and after randomized, controlled trial participation in Cameroon. Sex Transm Dis 32 (2005) 300
13. Food and Drug Administration Center for Biologics Evaluation and Research: Summary minutes, vaccines and related biological products advisory committee. Meeting #88 November 28-29, 2001, Bethesda, Maryland.
14. Block S.L., Nolan T., Sattler C., et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 118 (2006) 2135
15. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356 (2007) 1915
16. The FUTURE II Study Group. Effect of prophylactic human papillomavirus L1 virus-like particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomized clinical trials. Lancet 369 (2007) 1861
17. Garland S.M., Hernandez-Avila M., Wheeler C.M., et al., for the Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356 (2007) 1928
18. Joura E.A., Leodolter S., Hernandez-Avila M., et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulvar and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 369 (2007) 1693
19. Harper D.M., Franco E.I., Wheeler C.M., et al., for the HPV Vaccine Study group. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 (2006) 1247
20. Paavonen J., Jenkins D., Bosch F.X., and for the HPV PATRICIA study group. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369 (2007) 2161
21. Kjaer S.K., Tran T.N., Sparen P., et al. The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries. J Infect Dis 196 (2007) 1447
22. ACIP. Recommendations for the use of quadrivalent HPV vaccine. Available at. http://www.cdc.gov/hip/tech/provisionalrecs/hpv.pdf Accessed December 3, 2007
23. Gee J. Vaccine Safety Datalink Project: Monitoring the Safety of Quadrivalent Human Papillomavirus Vaccine (HPV 4). Presented at Advisory Committee on Immunization Practices Meeting, October 22, 2008. Atlanta, GA.
24. Calugar A. Quadrivalent Human Papillomavirus Vaccine (HPV 4): Post-licensure safety update, Vaccine Adverse Event Reporting System (VAERS), United States. Presented at Advisory Committee on Immunization Practices Meeting, October 22, 2008. Atlanta, GA
25. Steinbrook R. The potential of human papillomavirus vaccines. N Engl J Med 354 (2006) 1109